Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations.

To the Editor: A growing body of literature demonstrates that recombinase activating gene (RAG1/2) deficiency is seen in patients with autoimmune features and variable immunodeficiency, thus expanding the phenotype beyond T-/B-/NK+ severe combined immunodeficiency (SCID) and Omenn syndrome (OS) (1, 2). Based on data from SCID newborn screening programs in the United States and Puerto Rico, the estimated incidence of SCID is approximately 1:50,000 (3). Recent data from California’s SCID newborn screening identified RAG1/2 mutations in 28.6% of SCID/OS cases, for an incidence of about 1:250,000(4). However, this may not include individuals with less severe phenotypes caused by RAG1/2 defects. We present a family affected by compound heterozygous RAG1 mutations which resulted in a combined immunodeficiency phenotype with autoimmune cytopenias. We performed a population genetic analysis to estimate the incidence of disease caused by RAG1/2 homozygous or compound heterozygous mutations and found that the contribution of immune dysregulatory disease due to RAG1/2 mutations present in the general population may be much higher than previously estimated. Patient 1 (P1) is the eldest of five siblings born to non-consanguineous Caucasian parents (Figure 1, II.1). Clinical and laboratory data are summarized in Table 1 and Table E1 (online repository). Briefly, P1 developed early-onset autoimmune hemolytic anemia (AIHA), recurrent viral and bacterial infections, and nephrotic syndrome. Patient 2 (P2) is the full sibling of P1 (Figure 1, II.4), born full term with an eczematous rash. She developed recurrent bacterial and viral upper respiratory infections, early-onset AIHA, and neutropenia with antineutrophil antibodies. The autoimmune cytopenias did not respond to anti-CD20 treatment (rituximab). Both siblings had significantly reduced naive CD4+ T cell counts. Notable family history includes the siblings’ healthy mother who had false positive Rapid Plasma Reagin (RPR) antibodies and several maternal family members with multiple sclerosis. Figure 1 A. Sanger sequencing chromatogram of parents of the affected children confirms RAG1 mutation carrier status. Arrow indicates mutation position. B. Pedigree of family with RAG1 deficiency. Patient 1(II.1) and patient 2 (II.4) were affected with autoimmune ... Table 1 Clinical features and key laboratory data P1 underwent a 10/10 HLA-matched sibling bone marrow transplant at 8 years following conditioning with busulfan, fludarabine and anti-thymocyte globulin. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and methotrexate. One year post-transplant, P1 has excellent donor chimerism. Immune globulin replacement was discontinued 16 months post-transplant. P2 received a 10/10 matched unrelated marrow hematopoietic stem cell transplant (HSCT) at 29 months following similar conditioning. She had delayed engraftment of neutrophils with persistence of anti-neutrophil antibodies. Complications have included grade 3 gastrointestinal GVHD 6 months post-transplant, pancytopenia, and concern for graft failure. To identify an underlying genetic defect, P2 was screened for known mutations associated with SCID. No disease-causing mutations were identified in JAK3, DCLRE1C (ARTEMIS), IL7R, or RAG2. She harbored compound heterozygous mutations in exon 2 of RAG1, a genotype that was also confirmed for P1 (Figure 1). The c.1420C>T (p.Arg474Cys) mutation has previously been reported in cases of primary immunodeficiency, including SCID, Omenn syndrome and CD4+ T cell lymphopenia (Table E2, online repository). The c.2949delA (p.Lys983AsnfsX9) mutation is novel. Sanger sequencing of the remaining family members identified each parent as a RAG1 mutation carrier (Figure 1). The c.2949delA mutation is located at the carboxy-terminus of RAG1, at a RAG2 interaction site within the catalytic core (5, 6). A homozygous mutation at nearby amino acid position Q981P has been described by de Villartay et al.(7) with clinical features very similar to P1 and P2. Serum samples from healthy and affected family members were probed against an autoantibody protein microarray. IgG/IgM autoantibodies were increased in P1 and P2, and surprisingly, also in their mother (Figure E1 and Tables E3–E6, online repository). Furthermore, serum was tested for anticytokine antibodies that have been reported among patients with thymoma or autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED)(8, 9). Interestingly, our two affected patients also produce anti-interferon-α (IFNα) autoantibodies that were able to neutralize IFNα-induction of STAT1 phosphorylation in normal peripheral blood mononuclear cells, and may comprise a phenotypic signature for certain RAG-deficient patients (Figure E2, online repository). We assessed the European population carrier rate of RAG1/2 variants that have been identified in primary immunodeficiency diseases (PIDs; for methods, see Online Repository Text). Of more than 100 disease-causing RAG1 variants in the Human Gene Mutation Database, only 2 were present in 379 individuals of European ancestry in the 1000 Genomes database (Table E7, online repository). Seven and three unrelated individuals were heterozygous for the c.1346G>A and c.3016A>G disease-associated RAG1 variants, respectively. Therefore, the predicted population frequency based on Hardy-Weinberg equilibrium is 1:5746 individuals of European descent who are homozygous or compound heterozygous, much higher than what is expected for RAG1/2 SCID or OS cases. The single RAG2 disease-causing variant present in 1000 Genomes is in linkage disequilibrium with the c.3016A>G variant. Thus, the RAG1/2 carrier rate does not change. Our population genetic estimate indicates that RAG1 mutations likely contribute to many more undiagnosed cases of combined immunodeficiency, autoimmune cytopenias, and/or organ-specific autoimmune disease, although it is possible there is incomplete penetrance of these genotypes. California has a diverse and large Hispanic demographic and there may be differences when comparing estimates to a predominantly European population. Our estimate does not account for very rare RAG1 mutations not present in the 1000 Genomes database. Because limited data are available for functional activity in RAG1 variants identified in patients with PIDs, their disease-causing role cannot be easily established. In this case report, compound heterozygous RAG1 mutations resulted in a combined immunodeficiency phenotype with autoimmune cytopenias and multiple autoantibodies, including anti-IFNα antibodies as have been reported in APECED or thymoma patients. The mechanism for generation of these autoantibodies is unclear, but may depend on an underdeveloped thymus with decreased AIRE expression. The mother has a history of false-positive RPR and demonstrated presence of elevated levels of autoantibodies that was not seen in the c.1420C>T male carriers. Our findings suggest that the c.2949delA variant, even in heterozygous state, may contribute to generation of autoantibodies in RAG1-related disease. In patients with autoimmune cytopenias, lymphopenia and moderate-to-severe infections, screening for RAG1/2 mutations may well be worthwhile to identify molecular pathogenesis and treatment options. In our cohort, the presence of mild lymphopenia, autoimmune cytopenias, and a skewed naive:memory T cell ratio led to the diagnosis of RAG1 deficiency and subsequent HSCT. Earlier identification of a monogenic immune disorder and prompt HSCT during infancy might have spared progressive autoimmune complications. These findings provide additional data that RAG has important implications in both immunodeficiency and autoimmune diseases.